WO2022062301A1 - 一种氢化镁在制备防治慢性牙周炎的组合物中的应用及氢化镁牙膏 - Google Patents
一种氢化镁在制备防治慢性牙周炎的组合物中的应用及氢化镁牙膏 Download PDFInfo
- Publication number
- WO2022062301A1 WO2022062301A1 PCT/CN2021/075140 CN2021075140W WO2022062301A1 WO 2022062301 A1 WO2022062301 A1 WO 2022062301A1 CN 2021075140 W CN2021075140 W CN 2021075140W WO 2022062301 A1 WO2022062301 A1 WO 2022062301A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- magnesium hydride
- toothpaste
- magnesium
- composition
- hydride
- Prior art date
Links
- 239000000606 toothpaste Substances 0.000 title claims abstract description 91
- 229910012375 magnesium hydride Inorganic materials 0.000 title claims abstract description 89
- 229940034610 toothpaste Drugs 0.000 title claims abstract description 87
- 201000001245 periodontitis Diseases 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 208000001277 chronic periodontitis Diseases 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title claims abstract 26
- 239000002245 particle Substances 0.000 claims abstract description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 24
- 235000011187 glycerol Nutrition 0.000 claims description 14
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 13
- 239000000377 silicon dioxide Substances 0.000 claims description 12
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 11
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 11
- 235000001050 hortel pimenta Nutrition 0.000 claims description 11
- 244000246386 Mentha pulegium Species 0.000 claims description 10
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 10
- 235000012239 silicon dioxide Nutrition 0.000 claims description 10
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000005662 Paraffin oil Substances 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 239000000230 xanthan gum Substances 0.000 claims description 5
- 229920001285 xanthan gum Polymers 0.000 claims description 5
- 235000010493 xanthan gum Nutrition 0.000 claims description 5
- 229940082509 xanthan gum Drugs 0.000 claims description 5
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000013772 propylene glycol Nutrition 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 241001479543 Mentha x piperita Species 0.000 claims 1
- 229910052710 silicon Inorganic materials 0.000 claims 1
- 239000010703 silicon Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 28
- 206010006326 Breath odour Diseases 0.000 abstract description 23
- 239000001257 hydrogen Substances 0.000 abstract description 14
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 13
- 208000028169 periodontal disease Diseases 0.000 abstract description 13
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 abstract description 11
- 229910001425 magnesium ion Inorganic materials 0.000 abstract description 11
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 7
- 230000000740 bleeding effect Effects 0.000 abstract description 7
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 7
- 230000001954 sterilising effect Effects 0.000 abstract description 6
- 208000006386 Bone Resorption Diseases 0.000 abstract description 4
- 230000024279 bone resorption Effects 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 2
- 238000011161 development Methods 0.000 abstract description 2
- 208000002064 Dental Plaque Diseases 0.000 abstract 1
- 208000032139 Halitosis Diseases 0.000 abstract 1
- 239000010419 fine particle Substances 0.000 abstract 1
- 201000005562 gingival recession Diseases 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- RSHAOIXHUHAZPM-UHFFFAOYSA-N magnesium hydride Chemical compound [MgH2] RSHAOIXHUHAZPM-UHFFFAOYSA-N 0.000 description 61
- 206010018276 Gingival bleeding Diseases 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 206010018291 Gingival swelling Diseases 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000003239 periodontal effect Effects 0.000 description 8
- 239000011521 glass Substances 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 210000000214 mouth Anatomy 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 230000007717 exclusion Effects 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 208000002925 dental caries Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000009854 mucosal lesion Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000001680 brushing effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- 208000005888 Periodontal Pocket Diseases 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
- 239000000347 magnesium hydroxide Substances 0.000 description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000191070 Escherichia coli ATCC 8739 Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AQLLBJAXUCIJSR-UHFFFAOYSA-N OC(=O)C[Na] Chemical compound OC(=O)C[Na] AQLLBJAXUCIJSR-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000036344 tooth staining Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000007222 ypd medium Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
- A61K8/8176—Homopolymers of N-vinyl-pyrrolidones. Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to the technical field of toothpaste, in particular to the application of magnesium hydride in the preparation of a composition for preventing and treating chronic periodontitis and a magnesium hydride toothpaste.
- Toothpaste is a necessities of human daily life. With the improvement of people's living standards, changes in dietary content, neglect of oral hygiene, or imbalance of oral flora have led to a significant increase in the prevalence of periodontal disease, which is characterized by no distinction between young and old, and regardless of gender.
- Periodontal disease is mainly due to a series of clinical symptoms such as gingival bleeding, swelling, and ulcers caused by bacterial infection.
- periodontal disease can also lead to resorption of alveolar bone, resulting in loosening and loss of teeth.
- periodontal disease will not only promote the spread of periodontal bacteria through the blood and lymphoid tissues of the damaged part, thereby affecting other organs and endangering human health, but also affecting mental health through persistent neuropathic pain, causing depression, for example, Mania, anxiety and other mental illnesses.
- the toothpaste on the market mainly adopts the scheme of adding peroxide, and the peroxide produces the effect of sterilization and disinfection, so as to keep the oral environment clean.
- Another scheme is to use traditional Chinese medicine ingredients (for example, patent document CN102860971A describes a kind of preparation by adding natural propolis and traditional Chinese medicines with analgesic, anesthetic and anti-allergic effects as main efficacy preparations, compound traditional western medicines, supplemented by biotechnology Compound toothpaste with both antibacterial, anti-inflammatory and anti-acid desensitization)
- its disadvantage is that all kinds of traditional Chinese medicine additives may cause obvious side effects, and the ingredients of traditional Chinese medicine are unknown, and the efficacy is not accurate, which makes such products unable to enter the international market.
- periodontal disease is mainly caused by periodontal bacteria, which leads to inflammatory response and alveolar bone resorption, sterilization, anti-inflammatory and inhibition of alveolar bone resorption are the keys to preventing or treating the disease.
- the problem to be solved by the present invention is to provide an application of magnesium hydride in the preparation of a composition for preventing and treating chronic periodontitis and a magnesium hydride toothpaste.
- a magnesium hydride toothpaste In addition to the effect of sterilization, anti-inflammatory, improving gingival swelling or bleeding, improving bad breath or bad breath, removing tooth stains and whitening, and its low cost, it has dual effects of health care and treatment.
- the invention provides an application of magnesium hydride in preparing a composition for preventing and treating chronic periodontitis.
- the weight percentage of magnesium hydride is 1-3%.
- the particle size of the magnesium hydride is 0.1-100um.
- the invention provides an application of magnesium hydride in the preparation of toothpaste.
- the weight percentage of magnesium hydride is 1-3%.
- the particle size of the magnesium hydride is 0.1-100um.
- the invention provides a magnesium hydride toothpaste, comprising the following components by weight percentage:
- the toothpaste comprises the following components by weight: 51% glycerin, 42% calcium carbonate, 2% silicon dioxide, 3% sodium lauryl sulfate, 1% magnesium hydride, 1% peppermint powder .
- the toothpaste comprises the following components by weight: 33.4% paraffin oil, 14.3% glycerin, 43% calcium carbonate, 2% silicon dioxide, 3% sodium lauryl sulfate, 1% carboxymethyl Sodium cellulose, 0.3% xanthan gum, 2% magnesium hydride, 1% peppermint powder.
- the toothpaste comprises the following components by weight: 29% 1,2-propylene glycol, 15% glycerin, 44% calcium carbonate, 5% silicon dioxide, 3% polyvinylpyrrolidone, 3% magnesium hydride , 1% peppermint powder.
- the particle size of the magnesium hydride is 0.1-100um.
- the magnesium hydride of the present invention will react with water to generate magnesium hydroxide and hydrogen gas, and the magnesium hydroxide will be degraded into magnesium ions in the oral acid environment, and simultaneously promote the oral environment to be neutral or weakly alkaline. As small molecules, hydrogen molecules can freely penetrate tissues and cells and reach any location.
- the toothpaste containing magnesium hydride can effectively whiten, sterilize and anti-inflammatory, and at the same time can effectively prevent periodontal disease. Occurrence and development of disease.
- the present invention has the following beneficial effects:
- the present invention provides a new toothpaste-magnesium hydride toothpaste that can release hydrogen and magnesium ions in the process of brushing teeth.
- part of the toothpaste is placed in water, and by detecting the hydrogen concentration and magnesium ion concentration in the water, it is confirmed that the magnesium hydride toothpaste can significantly release hydrogen and magnesium ions; by testing the bactericidal activity, it is confirmed that the magnesium hydride toothpaste can effectively kill bacteria; Through small-scale clinical experiments, it has been confirmed that magnesium hydride toothpaste has preventive and therapeutic effects on chronic periodontitis.
- magnesium hydride toothpaste can alleviate periodontal disease: 50 patients with chronic periodontitis were selected, and the inclusion criteria were: good general health, no important systemic diseases; aged between 18 and 60 years old. Exclusion criteria: open caries or mucosal lesions in the oral cavity; severe periodontitis. How to use: 2 grams of toothpaste each time, 2 times a day, brush your teeth for 3 minutes. Continuous use for 30 days. (Organization unit: Shanghai Jiading District Dental Institute, which has been approved by the Ethics Committee.) Through this experiment, it was found that magnesium hydride toothpaste has effects on improving bleeding gums, red and swollen gums, bad breath or bad breath, and removing stains on teeth (selected by the present invention).
- the magnesium hydride toothpaste of the present invention is simple in preparation method, low in cost, non-toxic and free of side effects, has good anti-inflammatory, improves bleeding gums, red and swollen gums, bad breath or bad breath, removes stains on teeth, etc., thereby preventing and relieving Clinical symptoms caused by periodontal disease.
- magnesium hydride toothpaste with similar effect to the following examples can be prepared.
- Example 1 Prepare a toothpaste, which is composed of the following components by weight: 51% glycerin, 42% calcium carbonate, 2% silicon dioxide, 3% sodium lauryl sulfate, 1% magnesium hydride (granular diameter is 10-30um), 1% mint powder.
- Toothpaste is prepared as follows:
- Magnesium hydride particles are composed of MgH2 compound particles with a particle size of 0.1-100um.
- the toothpaste paste can be prepared by the traditional toothpaste preparation process. Specifically, the preparation method of the magnesium hydride toothpaste in this embodiment is as follows: after weighing the above-mentioned raw material components, disperse and mix in a pre-dispersing kettle, and open the vacuum pump of the paste kettle to inhale the above-mentioned liquid material. Then open the scraper, stirrer and colloid mill, turn off the colloid mill, stirrer and scraper in turn after 50 minutes, break the vacuum, obtain magnesium hydride toothpaste, and take samples for testing.
- Example 2 Prepare a toothpaste, which is composed of the following components by weight: 33.4% paraffin oil, 14.3% glycerin, 43% calcium carbonate, 2% silicon dioxide, 3% sodium lauryl sulfate, 1% Sodium carboxymethylcellulose, 0.3% xanthan gum, 2% magnesium hydride (particle size is 10-30um), 1% peppermint powder.
- Example 2 According to the preparation method of Example 1, the magnesium hydride toothpaste of Example 2 was obtained.
- Example 3 Prepare a toothpaste, which is composed of the following components by weight percentage: 29% 1,2-propanediol, 15% glycerin, 44% calcium carbonate, 5% silicon dioxide, 3% polyvinylpyrrolidone, 3% Magnesium hydride (particle size is 10-30um), 1% peppermint powder.
- Example 3 According to the preparation method of Example 1, the magnesium hydride toothpaste of Example 3 was obtained.
- the toothpaste of the invention is added with magnesium hydride, which has anti-oxidation-removal of tooth stain and whitening effect, and at the same time, effectively inhibits inflammatory reaction, has good stability, and can effectively prevent and delay a series of clinical symptoms caused by periodontitis.
- Comparative Example 1 A toothpaste was prepared, which was composed of the following components by weight: 51% glycerin, 43% calcium carbonate, 2% silicon dioxide, 3% sodium lauryl sulfate, 1% peppermint powder.
- Comparative Example 2 A toothpaste was prepared, which was composed of the following components by weight: 51% glycerin, 42.5% calcium carbonate, 2% silicon dioxide, 3% sodium lauryl sulfate, 0.5% magnesium hydride (granular diameter is 10-30um), 1% mint powder.
- Example 1-3 Materials: the magnesium hydride toothpaste of Example 1-3 (several toothbrushes, hydrogen measuring instrument (ENT2000, Co., Ltd., Japan), ultrasonic instrument, water, several small glasses (15ml volume), ICP-AES analyzer (atomic) emission spectrometer, USA).
- the hydrogen measuring instrument detects the hydrogen concentration when the small glass is left standing for 1min and 3min respectively.
- Example 1 Magnesium hydride toothpaste 900 1100 5.0
- Example 2 Magnesium hydride toothpaste 950 1200 7.7
- Example 3 Magnesium hydride toothpaste 990 1400 10.0
- Magnesium hydride toothpaste can generate high concentration of hydrogen and magnesium ions.
- the toothpaste formula used was the formula described in Example 1 (glycerol+magnesium hydride formula).
- Inclusion criteria good general health, no important systemic diseases; age between 18 and 60 years old.
- Exclusion criteria open caries or mucosal lesions in the oral cavity; severe periodontitis.
- Inclusion criteria aged 18 to 60 years old; diagnosed with chronic periodontitis through clinical examination (refer to the diagnostic criteria for chronic periodontitis proposed by the American Symposium on the Classification of Periodontal Diseases in 1999); subjects had at least 18 gums in their mouths Completely erupted teeth; subjects have periodontal pocket depths of 6-9 mm at ⁇ 4 sites in at least 2 quadrants of the oral cavity; willing to sign the informed consent, voluntary and able to ensure follow-up according to the research progress at the specified time Review and treatment.
- Exclusion criteria smokers, alcohol abusers, and drug abusers; those who have received antibiotics or periodontal sequence therapy within the past 3 months; those with uncontrolled diabetes, hypertension, and other systemic diseases that cannot tolerate periodontal sequence therapy; Those who have acute symptoms; those who are taking drugs that affect periodontal status (glucocorticoids, phenytoin, nifedipine, cyclosporine A, etc.); those who are pregnant or breastfeeding, or who plan to become pregnant during the planned treatment.
- Toothpaste containing 1% magnesium hydride can effectively improve gingival bleeding, gingival swelling and bad breath or bad breath.
- Inclusion criteria good general health, no important systemic diseases; age between 18 and 60 years old.
- Exclusion criteria open caries or mucosal lesions in the oral cavity; severe periodontitis.
- Toothpaste containing 2% magnesium hydride can effectively improve gingival bleeding, gingival swelling and bad breath or bad breath.
- Inclusion criteria good general health, no important systemic diseases; age between 18 and 60 years old.
- Exclusion criteria open caries or mucosal lesions in the oral cavity; severe periodontitis.
- Toothpaste containing 2% magnesium hydride can effectively improve gingival bleeding, gingival swelling and bad breath or bad breath.
- Example 3 Based on the clinical use effects of Example 1, Example 2 and Example 3, the magnesium hydride content within 1%-3% has a significant effect, which can effectively improve gingival bleeding, gingival swelling and bad breath or bad breath. There was no significant difference in effect between the three examples within the 1%-3% content.
- Inclusion criteria good general health, no important systemic diseases; age between 18 and 60 years old.
- Exclusion criteria open caries or mucosal lesions in the oral cavity; severe periodontitis.
- Toothpaste without magnesium hydride components (the rest of the components are the same as in Example 1), has a good effect on the oral cleaning of the subjects, but has no obvious improvement effect on gingival bleeding, gingival redness and bad breath or bad breath. . Comparing the effects of Example 1, it can be confirmed that the magnesium hydride component in the toothpaste formulation has a significant contribution to improving gingival bleeding, gingival swelling, and bad breath or bad breath.
- Test samples magnesium hydride toothpastes prepared in Example 1, Example 2, and Example 3; containing 1%, 2%, and 3% of magnesium hydride, respectively.
- the toothpastes prepared in Comparative Example 1 and Comparative Example 2 contained magnesium hydride at 0% and 0.5%, respectively (the remaining components were the same as in Experimental Example 1, so as to be compared with Example 1).
- Test strains Escherichia coli ATCC 8739; Staphylococcus aureus ATCC 25923; Candida albicans.
- LB medium for Escherichia coli, Staphylococcus aureus culture
- YPD medium for Candida albicans culture
- the experimental results are shown in Table 6.
- the toothpaste of the present invention has anti-common Escherichia coli, Staphylococcus aureus and Candida albicans have obvious bactericidal effect.
- the control group (without MgH 2 ) and the control toothpaste containing low content of MgH 2 (0.5%) had no obvious bactericidal effect on Escherichia coli.
- the toothpaste containing the magnesium hydride component (in the range of 1-3wt%) of the present invention has significant antibacterial properties, improves gingival bleeding, gingival swelling and eliminates bad breath or bad breath obvious effect.
Abstract
一种氢化镁在制备防治慢性牙周炎的组合物中的应用及氢化镁牙膏，所述组合物或氢化镁牙膏中氢化镁的重量百分含量为1-3％。该牙膏具有杀菌、抗炎、抗氧化、去除牙齿色斑、改善口气或者口臭、缓解牙龈红肿、出血、牙龈退缩、改善牙周炎症状的功效。还公开了一种氢化镁在制备防治慢性牙周炎的组合物中的应用。在牙膏膏体内添加了适量氢化镁微细颗粒，而氢化镁颗粒可以水解成具有抗炎作用的氢气和镁离子，还可以抑制牙槽骨吸收。该含有氢化镁的组合物使用安全，长期使用还能够有效预防牙周疾病的发生和发展。
Description
本发明涉及牙膏技术领域，具体地说，涉及一种氢化镁在制备防治慢性牙周炎的组合物中的应用及氢化镁牙膏。
刷牙的功效是清洁牙齿，维持口腔卫生。牙膏是人类日常生活必需品。随着人们生活水平的提高，饮食内容改变、忽视口腔卫生或者口腔菌群失调等原因，导致牙周疾病患病率明显增加，且呈现无分老幼，不分男女的特征。
牙周疾病主要是由于细菌感染导致的牙龈出血，肿胀，溃疡等一系列临床症状，此外牙周疾病亦可导致牙槽骨重吸收，进而引起牙齿松动脱落。尤其是牙周疾病不仅会促使牙周部细菌通过受损部位的血液，淋巴组织进行传播，从而累及其他器官，危害人体健康，还会通过持续的神经性疼痛，影响精神健康，诱发例如抑郁，狂躁，焦虑等精神性疾病。
可见，如何有效治疗或者缓解牙周疾病已成为影响公众健康的课题。目前需要一种持续稳定且副作用小的新型牙膏，在日常刷牙过程中使用，对可能产生的牙周疾病起到一定的预防作用，对已经产生的牙周疾病进行控制或治疗。
目前，市场上的牙膏主要采用添加过氧化物的方案，以过氧化物产生杀菌消毒的效果，从而保持口腔环境的清洁。但是其作用单一，使用寿命短。另一种方案是使用中药成分(如专利文献CN102860971A中记载了一种通过加入采用天然蜂胶和具有镇痛、麻醉、抗过敏作用的中药为主要功效制剂，复方传统西药，辅以生物技术制成兼具抗菌消炎和防酸脱敏的复方牙膏)，其缺点是各类中药添加剂可能会导致明显副作用，且中药成分不明，功效不确切，导致这类产品无法进入国际市场。
由于牙周疾病主要由牙周细菌引起，导致炎症反应及牙槽骨重吸收，所以杀菌、抗炎和抑制牙槽骨重吸收是预防或治疗该疾病的关键。
发明内容
本发明拟解决的问题是提供一种氢化镁在制备防治慢性牙周炎的组合物中的应用及氢化镁牙膏，所述氢化镁牙膏为一种新型牙膏组份配方，除日常牙齿及口腔清洁的效果外，其还具有杀菌、消炎、改善牙龈红肿或出血、改善口臭或口气、去除牙齿色斑美白等作用，而且其成本低廉，具有保健和治疗双重功效。
本发明的目的是通过以下技术方案实现的：
本发明提供了一种氢化镁在制备防治慢性牙周炎的组合物中的应用，所述组合物中，氢化镁的重量百分比含量为1-3％。
优选地，所述氢化镁的颗粒粒径为0.1-100um。
本发明提供了一种氢化镁在制备牙膏中的应用，所述牙膏中，氢化镁的重量百分比含量为1-3％。
优选地，所述氢化镁的颗粒粒径为0.1-100um。
本发明提供了一种氢化镁牙膏，包括下述重量百分比含量的各组分：
15-51％甘油和/或石蜡油，
0-30％1,2-丙二醇，
42-45％碳酸钙，
2-5％二氧化硅，
0-3％十二烷基硫酸钠，
1-3％氢化镁，
0-1％羧甲基纤维素钠，
0-0.3％黄原胶，
0-3％聚乙烯吡咯烷酮，
0-1％薄荷粉。
优选地，所述牙膏包括下述重量百分比含量的各组分：51％甘油，42％碳酸钙，2％二氧化硅，3％十二烷基硫酸钠，1％氢化镁，1％薄荷粉。
优选地，所述牙膏包括下述重量百分比含量的各组分：33.4％石蜡油，14.3％甘油，43％碳酸钙，2％二氧化硅，3％十二烷基硫酸钠，1％羧甲基纤维素钠，0.3％黄原胶，2％氢化镁，1％薄荷粉。
优选地，所述牙膏包括下述重量百分比含量的各组分：29％1,2-丙二醇，15％甘油，44％碳酸钙，5％二氧化硅，3％聚乙烯吡咯烷酮，3％氢化镁，1％薄荷粉。
优选地，所述氢化镁的颗粒粒径为0.1-100um。
本发明所述的氢化镁遇水后会反应生成氢氧化镁和氢气，氢氧化镁会在口腔酸性环境下被降解成镁离子，同时促使口腔环境呈中性或弱碱化。氢分子作为小分子可以自由穿透组织和细胞，到达任何位置。
因此，本发明通过氢气和镁离子的杀菌、抗氧化，抗炎，抑制骨吸收的作用，使用含氢化镁的牙膏，可以起到有效的美白、杀菌、抗炎作用，同时可有效预防牙周疾病的发生和发展。
与现有技术相比，本发明具有如下的有益效果：
1、本发明提供了一种在刷牙过程中能释放氢气和镁离子的新牙膏——氢化镁牙膏。本发明取部分牙膏置于水内，通过检测水内氢气浓度和镁离子浓度，证实了氢化镁牙膏可以显著释放氢气和镁离子；通过测试杀菌活性，证实了氢化镁牙膏能够有效杀灭细菌；通过小规模临床实验，证实了氢化镁牙膏对慢性牙周炎有防治作用。
2、本发明发现了氢化镁牙膏可以缓解牙周疾病：挑选慢性牙周炎患者50人，纳入标准：全身健康状况良好、无重要的全身系统性疾病；年龄在18周岁～60周岁。排除标准：口腔内有开放性龋齿或粘膜病变；患严重的牙周炎。使用方法：每人每天2次，每次2克牙膏，刷牙3分钟。持续使用30天。(组织单位：上海市嘉定区牙防所，已通过伦理委员会批准。)通过该实验发现氢化镁牙膏对改善牙龈出血、牙龈红肿、口臭或口气、去除牙齿色斑等均有效果(本发明挑选了5组慢性牙周炎患者(分别对应0wt％MgH
2(除不含MgH
2外，其余组分和实施例1同)、0.5wt％MgH
2、1wt％MgH
2、2wt％MgH
2、3wt％MgH
2五种含量的牙膏)、每组患者50人。一共是250人做相关的临床试验，详见效果验证二：氢化镁牙膏对慢性牙周炎患者的治疗研究)。
3、本发明的氢化镁牙膏制备方法简单，成本低，且无毒无副作用，具有良好的消炎、改善牙龈出血、牙龈红肿、口臭或口气、去除牙齿色斑等作用，进而起到预防和缓解牙周疾病引起的临床症状。
下面结合具体实施例对本发明进行详细说明。以下实施例将有助于本领域的技术人员进一步理解本发明，但不以任何形式限制本发明。应当指出的是，对本领域的普通技术人员来说，在不脱离本发明构思的前提下，还可以做出若干变形和改进。这些都属于本发明的保护范围。
需要说明的是，在下述实施例中，氢化镁采用颗粒粒径为0.1-100um中的任意粒 径取值时，都能制备具有与下述实施例相似效果的氢化镁牙膏。
实施例1：配置一种牙膏，由下述组分按重量百分比组成：51％甘油，42％碳酸钙，2％二氧化硅，3％十二烷基硫酸钠，1％氢化镁(颗粒粒径为10-30um)，1％薄荷粉。
牙膏制备如下：
氢化镁颗粒由粒径为0.1-100um的MgH2化合物颗粒组成。牙膏膏体采用传统牙膏制备工艺即可制备。具体本实施实例氢化镁型牙膏的制备方法为：将上述原料组分称重后，在预分散釜中分散，混合，开制膏釜真空泵吸入上述液料。然后开刮刀，搅拌器和胶体磨，50分钟后依次关闭胶体磨，搅拌器和刮刀，破真空，得到氢化镁型牙膏，取样检测。
实施例2：配置一种牙膏，由下述组分按重量百分比组成：33.4％石蜡油，14.3％甘油，43％碳酸钙，2％二氧化硅，3％十二烷基硫酸钠，1％羧甲基纤维素钠，0.3％黄原胶，2％氢化镁(颗粒粒径为10-30um)，1％薄荷粉。
按照实例1的制备方法，得到实例2的氢化镁型牙膏。
实施例3：配置一种牙膏，由下述组分按重量百分比组成：29％1,2-丙二醇，15％甘油，44％碳酸钙，5％二氧化硅，3％聚乙烯吡咯烷酮，3％氢化镁(颗粒粒径为10-30um)，1％薄荷粉。
按照实例1的制备方法，得到实例3的氢化镁型牙膏。
本发明牙膏添加了氢化镁成分，能够抗氧化-去除牙齿色斑和美白功效、同时有效抑制炎症反应，稳定性好，可以有效预防缓建牙周炎引起的一系列临床症状。
对照例1：配置一种牙膏，由下述组分按重量百分比组成：51％甘油，43％碳酸钙，2％二氧化硅，3％十二烷基硫酸钠，1％薄荷粉。
牙膏制备流程同实施例1。
对照例2：配置一种牙膏，由下述组分按重量百分比组成：51％甘油，42.5％碳酸钙，2％二氧化硅，3％十二烷基硫酸钠，0.5％氢化镁(颗粒粒径为10-30um)，1％薄荷粉。
牙膏制备流程同实施例1。
效果验证：
一、氢化镁牙膏的释放氢气和镁离子浓度测定
1实验方法
1.1材料：实施例1-3的氢化镁牙膏(牙刷若干把，测氢气仪(ENT2000，株式会社，日本)，超声仪，水，小玻璃杯(15ml容积)若干，ICP-AES分析仪(atomic emission spectrometer，美国)。
1.2实验步骤：
1)将氢化镁牙膏涂于牙刷上。
2)将牙刷置于含5ml水的小玻璃杯内，涂抹牙膏于玻璃壁上。
3)将小玻璃杯置于超声仪中1min，促使牙膏溶解。取出小玻璃杯，室温静置。
4)测氢气仪分别检测小玻璃杯静置1min和3min时氢气浓度。
5)采用ICP-AES检测镁离子浓度。
6)每个实例重复五次，结果用平均值加减标准差显示。
2.氢气和镁离子浓度测试结果如表1所示
表1
| 样品 | 1min氢气(ppb) | 3min氢气(ppb) | 镁离子浓度(ppm) |
| 实例1氢化镁牙膏 | 900 | 1100 | 5.0 |
| 实例2氢化镁牙膏 | 950 | 1200 | 7.7 |
| 实例3氢化镁牙膏 | 990 | 1400 | 10.0 |
3.结论：氢化镁牙膏可以产生高浓度氢气和镁离子。
二、氢化镁牙膏对慢性牙周炎患者的治疗研究
(一)实施例1临床使用效果：
受试对象50例。
使用的牙膏配方为实施例1所述的配方(甘油+氢化镁配方)。
纳入标准：全身健康状况良好、无重要的全身系统性疾病；年龄在18周岁～60周岁。
排除标准：口腔内有开放性龋齿或粘膜病变；患严重的牙周炎。
使用方法：每人每天2次，每次2克牙膏，刷牙3分钟。持续使用30天。
组织单位：上海市嘉定区牙防所，已通过伦理委员会批准。
实验结束后对参加实验人员进行调查问卷。整理得到效果反馈如表2所示。
表2 实施例1的氢化镁牙膏使用效果反馈表
2.实验对象：
入组标准：年龄18～60岁；通过临床检查确诊为慢性牙周炎(参照1999年美国牙周病分类研讨会提出的慢性牙周炎的诊断标准)；受试者口腔内至少有18颗完全萌出的牙齿；受试者至少在口腔的2个象限中有≥4个位点的牙周袋深度在6～9mm；愿意签署知情同意书，自愿并能够确保在规定时间按研究进度进行随访复查和治疗。
排除标准：吸烟、酗酒、药物滥用者；近3个月内接受过抗生素或者牙周序列治疗者；患有未控制的糖尿病、高血压以及其他不能耐受牙周序列治疗的全身系统疾病者；存在急性症状者；正在服用影响牙周状况的药物(糖皮质激素、苯妥英、硝苯地平、环孢霉素A等)者；孕期或哺乳期，或在计划治疗期间有怀孕打算者。
伦理委员会批准。患者签署知情同意书。
干预和临床检查
5组患者均进行口腔卫生宣教及超声龈上洁治，1周后检查牙周各项临床指标(基线水平)，然后用龈下刮治器进行SRP，检查牙周袋及根面，确认为已对根面进行了充分的清理和平整。5组患者分别用各组的牙膏刷牙，使用专用牙刷(牙防所提供)，指导正确的刷牙方法。所有纳入患者在龈上洁治后l周(基线)、6周和12周进行全面的牙周临床检查。临床检查指标包括:牙周探诊深度(Probing pocket depth，PD)、临床附着水平(clinical attachment level，CAL)、探诊出血指数(bleeding on probing，BOP)。
3.结论：含有1％氢化镁牙膏可以有效改善牙龈出血、牙龈红肿及口臭或口气。
(二)实施例2临床使用效果
受试对象50例
纳入标准：全身健康状况良好、无重要的全身系统性疾病；年龄在18周岁～60周岁。
排除标准：口腔内有开放性龋齿或粘膜病变；患严重的牙周炎。
使用方法：每人每天2次，每次2克牙膏，刷牙3分钟。持续使用30天。
组织单位：上海市嘉定区牙防所，已通过伦理委员会批准。
整理得到效果反馈如表3所示。
表3实施例2的氢化镁牙膏使用效果反馈表
结论：含有2％氢化镁牙膏可以有效改善牙龈出血、牙龈红肿及口臭或口气。
(三)实施例3临床使用效果
受试对象50例
纳入标准：全身健康状况良好、无重要的全身系统性疾病；年龄在18周岁～60周岁。
排除标准：口腔内有开放性龋齿或粘膜病变；患严重的牙周炎。
使用方法：每人每天2次，每次2克牙膏，刷牙3分钟。持续使用30天。
组织单位：上海市嘉定区牙防所，已通过伦理委员会批准。
整理得到效果反馈如表4所示。
表4实施例3的氢化镁牙膏使用效果反馈表
| 很好(人数) | 一般(人数) | 几乎没有(人数) | 完全没有(人数) |
| 清洁力 | 42 | 8 | 0 | 0 |
| 牙龈出血改善 | 22 | 19 | 8 | 1 |
| 牙龈红肿改善 | 25 | 19 | 5 | 1 |
| 口臭或口气改善 | 41 | 5 | 3 | 1 |
结论：含有2％氢化镁牙膏可以有效改善牙龈出血、牙龈红肿及口臭或口气。
综合实施例1、实施例2和实施例3的临床使用效果看，氢化镁含量在1％-3％内效果显著，均可以有效改善牙龈出血、牙龈红肿及口臭或口气。在1％-3％含量内的三种实施例之间效果无显著性差异。
(四)对照例临床试验效果
对照例1牙膏(不含MgH
2，与实施例1对应)使用效果反馈表
受试对象50例
纳入标准：全身健康状况良好、无重要的全身系统性疾病；年龄在18周岁～60周岁。
排除标准：口腔内有开放性龋齿或粘膜病变；患严重的牙周炎。
结果如表5所示。
表5对照例1的氢化镁牙膏使用效果反馈表
结论：不含有氢化镁组分的牙膏(其余组分同实施例1)，对受试对象的口腔清洁大都有很好的效果，但是对牙龈出血、牙龈红肿及口臭或口气方面没有明显改善效果。对比实施例1的效果，可以确认氢化镁组分在本牙膏配比中对改善牙龈出血、牙龈红肿及口臭或口气方面具有显著的贡献。
三、MgH
2牙膏抗菌测试
1、实验目的：测试3种不同氢化镁含量牙膏的杀菌活性
2、实验材料
(1)测试样品：实施例1，实施例2，实施例3制备的氢化镁牙膏；分别含氢化镁1％、2％、3％。对照例1和对照例2制备的牙膏含氢化镁分别为0％、0.5％(其余组分同实验例1，以便和实施例1对照)。
(2)测试菌株：大肠杆菌ATCC 8739；金黄色葡萄球菌ATCC 25923；白色念珠菌。
(3)培养基：LB培养基(用于大肠杆菌、金黄色葡萄球菌培养)；YPD培养基(用于白色念珠菌的培养)。
3、实验方案
挑取单菌落至2mL液体培养基中，过夜培养；用相应培养基调整菌浓至OD
600约0.5，再用培养基稀释100倍作为菌悬液待用；称取不同牙膏或对照基质1g，加入菌悬液中(含2-3颗玻璃珠，用于分散牙膏)，振荡溶解牙膏，静置3min；用无菌生理盐水梯度稀释，用点种法对稀释样品计数，并计算杀菌率。
4、实验结果
表6 杀菌率(％)测试结果
实验结果如表6所示，与对照组1(不含MgH
2)和对照组2(低含量MgH
2(0.5％))的对照例相比相比，本发明牙膏具有对常见的大肠杆菌、金黄色葡萄球菌及白色念珠菌均具有明显的杀菌效果。而对照组(不含MgH
2)和含有低含量MgH
2(0.5％)的对照例牙膏，对大肠杆菌没有明显杀菌效果。
综合上述抗菌实验结果和5组临床受试者实际反馈结果，可以确认本发明含有氢化镁组分(1～3wt％范围)的牙膏具有显著的抗菌、改善牙龈出血、牙龈红肿及消除口臭或口气方面的明显功效。
本发明具体应用途径很多，以上所述仅是本发明的优选实施方式。应当指出，以上实施例仅用于说明本发明，而并不用于限制本发明的保护范围。对于本技术领域的普通技术人员来说，在不脱离本发明原理的前提下，还可以做出若干改进，这些改进也应视为本发明的保护范围。
Claims (9)
- 一种氢化镁在制备防治慢性牙周炎的组合物中的应用，其特征在于，所述组合物中，氢化镁的重量百分比含量为1-3％。
- 根据权利要求1所述的应用，其特征在于，所述氢化镁的颗粒粒径为0.1-100um。
- 一种氢化镁在制备牙膏中的应用，其特征在于，所述牙膏中，氢化镁的重量百分比含量为1-3％。
- 根据权利要求3所述的应用，其特征在于，所述氢化镁的颗粒粒径为0.1-100um。
- 一种氢化镁牙膏，其特征在于，包括下述重量百分比含量的各组分：15-51％甘油和/或石蜡油，0-30％1,2-丙二醇，42-45％碳酸钙，2-5％二氧化硅，0-3％十二烷基硫酸钠，1-3％氢化镁，0-1％羧甲基纤维素钠，0-0.3％黄原胶，0-3％聚乙烯吡咯烷酮，0-1％薄荷粉。
- 根据权利要求5所述的氢化镁牙膏，其特征在于，所述牙膏包括下述重量百分比含量的各组分：51％甘油，42％碳酸钙，2％二氧化硅，3％十二烷基硫酸钠，1％氢化镁，1％薄荷粉。
- 根据权利要求5所述的氢化镁牙膏，其特征在于，所述牙膏包括下述重量百分比含量的各组分：33.4％石蜡油，14.3％甘油，43％碳酸钙，2％二氧化硅，3％十二烷基硫酸钠，1％羧甲基纤维素钠，0.3％黄原胶，2％氢化镁，1％薄荷粉。
- 根据权利要求5所述的氢化镁牙膏，其特征在于，所述牙膏包括下述重量百分比含量的各组分：29％1,2-丙二醇，15％甘油，44％碳酸钙，5％二氧化硅，3％聚乙烯吡咯烷酮，3％氢化镁，1％薄荷粉。
- 根据权利要求5-8任一项所述的氢化镁牙膏，其特征在于，所述氢化镁的颗粒粒径为0.1-100um。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/614,548 US20220313570A1 (en) | 2020-09-23 | 2021-02-04 | Use of magnesium hydride in preparation of composition for preventing and treating chronic periodontitis, and magnesium hydride toothpaste |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011011374.5 | 2020-09-23 | ||
| CN202011011374.5A CN112057468A (zh) | 2020-09-23 | 2020-09-23 | 一种氢化镁在制备防治慢性牙周炎的组合物中的应用及氢化镁牙膏 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022062301A1 true WO2022062301A1 (zh) | 2022-03-31 |
Family
ID=73682659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2021/075140 WO2022062301A1 (zh) | 2020-09-23 | 2021-02-04 | 一种氢化镁在制备防治慢性牙周炎的组合物中的应用及氢化镁牙膏 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20220313570A1 (zh) |
| CN (2) | CN112057468A (zh) |
| WO (1) | WO2022062301A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112057468A (zh) * | 2020-09-23 | 2020-12-11 | 上海交通大学 | 一种氢化镁在制备防治慢性牙周炎的组合物中的应用及氢化镁牙膏 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100008849A1 (en) * | 2008-07-09 | 2010-01-14 | William John Martin | Method of generating hydrogen and of selectively transferring the generated hydrogen to drinking water as a potential source of alternative cellular energy (ACE) |
| WO2011061330A2 (de) * | 2009-11-20 | 2011-05-26 | Symrise Ag | Verwendung physiologischer kühlwirkstoffe und mittel enthaltend solche wirkstoffe |
| WO2012061698A2 (en) * | 2010-11-05 | 2012-05-10 | Senomyx, Inc. | Compounds useful as modulators of trpm8 |
| WO2019043164A1 (de) * | 2017-08-31 | 2019-03-07 | Basf Se | Verwendung physiologischer kühlwirkstoffe und mittel enthaltend solche wirkstoffe |
| WO2020023396A1 (en) * | 2018-07-23 | 2020-01-30 | Nutragenom, Llc | Composition and methods for generating and sustaining molecular hydrogen (h2) in aqueous systems |
| CN112057468A (zh) * | 2020-09-23 | 2020-12-11 | 上海交通大学 | 一种氢化镁在制备防治慢性牙周炎的组合物中的应用及氢化镁牙膏 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4143999A (en) * | 1998-05-15 | 1999-12-06 | Unilever Plc | Oral composition comprising capsules |
| EP2236144A1 (en) * | 2007-12-28 | 2010-10-06 | MIZ Co., Ltd. | External preparation for preventive or therapeutic use |
-
2020
- 2020-09-23 CN CN202011011374.5A patent/CN112057468A/zh active Pending
-
2021
- 2021-02-04 WO PCT/CN2021/075140 patent/WO2022062301A1/zh active Application Filing
- 2021-02-04 US US17/614,548 patent/US20220313570A1/en active Pending
- 2021-09-17 CN CN202111093462.9A patent/CN113577098B/zh active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100008849A1 (en) * | 2008-07-09 | 2010-01-14 | William John Martin | Method of generating hydrogen and of selectively transferring the generated hydrogen to drinking water as a potential source of alternative cellular energy (ACE) |
| WO2011061330A2 (de) * | 2009-11-20 | 2011-05-26 | Symrise Ag | Verwendung physiologischer kühlwirkstoffe und mittel enthaltend solche wirkstoffe |
| WO2012061698A2 (en) * | 2010-11-05 | 2012-05-10 | Senomyx, Inc. | Compounds useful as modulators of trpm8 |
| WO2019043164A1 (de) * | 2017-08-31 | 2019-03-07 | Basf Se | Verwendung physiologischer kühlwirkstoffe und mittel enthaltend solche wirkstoffe |
| WO2020023396A1 (en) * | 2018-07-23 | 2020-01-30 | Nutragenom, Llc | Composition and methods for generating and sustaining molecular hydrogen (h2) in aqueous systems |
| CN112057468A (zh) * | 2020-09-23 | 2020-12-11 | 上海交通大学 | 一种氢化镁在制备防治慢性牙周炎的组合物中的应用及氢化镁牙膏 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220313570A1 (en) | 2022-10-06 |
| CN113577098B (zh) | 2022-11-08 |
| CN113577098A (zh) | 2021-11-02 |
| CN112057468A (zh) | 2020-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20050180929A1 (en) | Ozone treatment of root canals | |
| WO2016011978A1 (zh) | 一种具有多重口腔治疗和保健功效的组合物及其制备方法 | |
| Swierkot et al. | Manual versus sonic-powered toothbrushing for plaque reduction in patients with dental implants: an explanatory randomised controlled trial. | |
| Iliadis et al. | Ozone and its use in periodontal treatment | |
| Howshigan et al. | The effects of an Ayurvedic medicinal toothpaste on clinical, microbiological and oral hygiene parameters in patients with chronic gingivitis: a double-blind, randomised, placebo-controlled, parallel allocation clinical trial | |
| BR112020002106B1 (pt) | Composição em gel, método de preparo e uso da mesma | |
| Jorgensen et al. | Periodontal antimicrobials—finding the right solutions | |
| Fure et al. | Evaluation of different fluoride treatments of initial root carious lesions in vivo. | |
| Denez et al. | Evaluation of a unique subgingival irrigation with 10% povidone-iodine after scaling and root planing: A randomized clinical trial. | |
| CN113577098B (zh) | 一种氢化镁在制备防治慢性牙周炎的组合物中的应用及氢化镁牙膏 | |
| Tuan et al. | Clinical and microbiologic study of periodontal surgery by means of apically positioned flaps with and without osseous recontouring. | |
| Sandhu | Ozone in Dentistry-A review | |
| Maru et al. | Reduction in Bacterial Loading using Papacarie and Carisolv as an Irrigant in Pulpectomized Primary Molars–A Preliminary Report | |
| US20030143164A1 (en) | Reductant rinse for use with ozone treatment of dental caries | |
| CN112076221B (zh) | 一种脱敏糊剂及其制备方法和用途 | |
| CN112220707A (zh) | 一种抗牙齿敏感生物溶菌酶牙膏组合物 | |
| Stallaert | A retrospective study of root canal therapy in non-vital primary molars | |
| Meenapriya et al. | Comparative evaluation of antimicrobial efficacy of herbal mouthwash versus commercially available mouthwash 2% chlorhexidine. | |
| Abinaya | Comparative Evaluation of Antimicrobial Efficacy of Bioactive Glass, 1% Chlorhexidine Gluconate with Calcium Hydroxide and 1% Chlorhexidine Gluconate, as Intracanal Medicament in Primary Molars | |
| Chhajer | OZONE: NATURE'S FILTER OF BAD PARTICLES. | |
| Abid et al. | Comparative efficacy of the antiplaque effect of natural honey mouthwash and chlorhexidine mouthwash. a randomized controlled trial | |
| Chanthasan et al. | Association between food impaction and peri-implant soft tissue condition at proximal space between implant supported single crown and natural teeth | |
| Sikri et al. | Ozone therapy in dentistry: Systematic review | |
| Songür et al. | Disinfection Effect of Gaseous Ozone on Candida albicans and Enterococcus faecalis: A Randomized Clinical Trial in Infected Primary Molars | |
| Prather | Effect of Antibiotic Pastes on Chemical Structure and Microhardness of Radicular Dentin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21870691 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 21870691 Country of ref document: EP Kind code of ref document: A1 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 21870691 Country of ref document: EP Kind code of ref document: A1 |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 25.09.2023) |